Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16472
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurphy, C-
dc.contributor.authorHawkes, E-
dc.contributor.authorChionh, Fiona-
dc.contributor.authorChong, Geoff-
dc.date2016-10-28-
dc.date.accessioned2017-01-02T23:13:36Z-
dc.date.available2017-01-02T23:13:36Z-
dc.date.issued2017-02-
dc.identifier.citationJournal of Clinical Pharmacy and Therapeutics 2017; 42(1): 111-114en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16472-
dc.description.abstractWHAT IS KNOWN AND OBJECTIVE: Human herpesvirus-8 (HHV-8)-positive, HIV-negative multicentric Castleman's disease is a rare lymphoproliferative disorder with no standardized treatment. Concurrent Kaposi's sarcoma, another HHV-8-related disease, is uncommon in HIV-negative patients. The role of antiviral therapy and rituximab in HIV-negative patients is not well established. CASE DESCRIPTION: We report a case of a 5-year, durable remission of HHV-8-positive, HIV-negative comorbid multicentric Castleman's disease and Kaposi's sarcoma treated with long-term valganciclovir, following initial rituximab and liposomal doxorubicin. WHAT IS NEW AND CONCLUSION: Currently, there is no defined role for antiviral therapy in the treatment of HIV-negative HHV-8-positive multicentric Castleman's disease and Kaposi's sarcoma. Ganciclovir followed by indefinite, continuous valganciclovir is thought to have contributed significantly to the durable response in this case.en_US
dc.subjectKaposi's sarcomaen_US
dc.subjectHuman herpesvirus-8en_US
dc.subjectMulticentric Castleman's diseaseen_US
dc.subjectValgancicloviren_US
dc.titleDurable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patienten_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Clinical Pharmacy and Therapeuticsen_US
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australiaen_US
dc.type.studyortrialCase Series and Case Reportsen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27790727en_US
dc.identifier.doi10.1111/jcpt.12472en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.